Please ensure Javascript is enabled for purposes of website accessibility
Taylor Carmichael

Taylor Carmichael

TMFSaintCroix

Taylor Carmichael is a former attorney and filmmaker. He's the author of a line of murder mysteries, including Whodidit in the Supreme Court? and Whodidit With a Senator? The majority of what he knows about stocks he learned right here at the Motley Fool.

Recent articles

scale-1

How Has Disney Stock Done Since January?

It's been a wild ride for the House of Mouse in 2020.


GettyImages-1064981344

If You Invested $10,000 in Teladoc in January, This Is How Much You'd Have Now

The stock has done quite well for shareholders in 2020.


GettyImages-1212665265

2 Stocks I Can't Wait to Buy When the Market Crashes Again

These investments have paid off since March's meltdown. Here's why another correction will bring attractive prices.


GettyImages-800433994

These 2 Stocks Have Doubled and Still Have Room to Grow

Silvergate Capital and fuboTV are both rocking in 2020, and each has plenty of potential to keep going in 2021.


GettyImages-649602004

These Were the 10 Best Healthcare Stocks of 2020

The highest performers of the year are biotechs fighting COVID-19 and cancer. Are they still buys for 2021?

GettyImages-1186712099

One Big Danger for Snowflake Investors

The stock is richly valued, and insiders will soon be able to sell.


GettyImages-1287178753

If You Invested $10,000 in Arcturus in January, This Is How Much You'd Have Now

Shares of the mRNA biotech have been soaring in 2020.


GettyImages-1221155808

Forget FAANG, Buy These 2 Unstoppable Stocks Instead

While tech stocks are overvalued, these investments have triple-digit revenue growth and incredible upside over the next decade.


GettyImages-1135068422

Up 1,000% in 2020, Is Co-Diagnostics Stock Still a Buy?

The company has unbelievable top-line growth right now, and has profit margins over 60%. Will the stock continue to ride high once the world is vaccinated?


GettyImages-1201312636

AstraZeneca COVID-19 Vaccine Achieves 70% Efficacy

The British pharmaceutical giant submits its phase 3 data to a peer-reviewed journal, the first company to do so.

0

How Did Trillium Stock Perform in 2020?

The micro-cap has shot up an incredible 1,400% this year.


GettyImages-465050849

Is Novavax Still a Buy After Jumping 3,000%?

The No. 1 stock of 2020 still has a lot of room to run... and a lot of room to fall.


GettyImages-1214966550

Why Is Everybody Talking About GrowGeneration?

The marijuana stock is up 778% so far in 2020.


416664

Why in the World Is Retractable Technologies Stock Up 566%?

Sales jumped 132% in the most recent quarter, as demand for the company's syringes have skyrocketed.


GettyImages-1254994179

Why Is Everybody Talking About Jumia Stock?

The bulls think it might be the next Sea Limited or MercadoLibre. The bears see horrible profit margins and revenues going backwards.

GettyImages-1204177559

Nano-X Stock Is Heading Higher

As we close in on Dec. 3 -- the day Nano-X will demonstrate its device to the Radiological Society of North America -- the bulls are charging and the shorts are fleeing. The stock jumped 17% on Monday.


GettyImages-1169308396

2 E-Commerce Stocks That Are Outperforming Amazon

Shareholders of Sea Limited and Farfetch dramatically outdid Amazon owners in 2020. What's going on?


GettyImages-1221692768

What Are the Odds That Novavax's Coronavirus Vaccine Is 90% Effective?

Pfizer and Moderna have reported vaccine efficacy of over 90%. What should Novavax investors expect?


GettyImages-518546769

Amarin vs. the Generics: Who Will Win?

After Amarin lost its patent rights in the U.S., the stock crashed overnight. Investors might want to stay optimistic.


GettyImages-1159049959 (1)

These 2 Under-the-Radar Stocks Are Great Buys Right Now

Freshpet and Afterpay have been stomping the market for years.